TNFα and IL-1β inhibitors are in clinical use for inflammatory diseases and autoimmune disorders [134,135,136] and were demonstrated to inhibit the aggressiveness phenotype of BC cells (as cited above). This evidence concerns the gene TNF and breast cancer.